Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analysts Provide Mixed Ratings and Lower Price Targets for 8×8

Elaine Mendonca by Elaine Mendonca
January 18, 2024
in Breaking News
0
Technology Data analytics Stock Exchange
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Over the past three months, a total of four analysts have shared their ratings on 8×8 (NASDAQ: EGHT), presenting a wide range of perspectives, from optimistic to pessimistic. Let’s take a look at their recent ratings and compare them to previous months to see how sentiments have shifted.

Rating Total Ratings Last 30 Days 1M Ago 2M Ago 3M Ago
Bullish 3 1 0 0 2
Somewhat Bullish 0 0 0 0 0
Indifferent 1 0 0 0 1
Somewhat Bearish 0 0 0 0 0
Bearish 0 0 0 0 0

In addition to providing ratings, these analysts have also evaluated 8×8 and shared their 12-month price targets. The average target stands at $4.00, with a high estimate of $5.00 and a low estimate of $2.50. However, it’s worth noting that the current average target represents a 15.79% decrease compared to the previous average target of $4.75, indicating a downward trend.

Let’s delve into some key insights from the analysts’ actions and evaluations:

1. Catharine Trebnick from Rosenblatt has downgraded the rating to Buy and set a current price target of $4.00, down from the previous target of $4.50.

2. Ryan Macwilliams from Barclays has also downgraded the rating to Equal-Weight and set a current price target of $2.50, down from $4.00.

3. On the other hand, George Sutton from Craig-Hallum has maintained the Buy rating and kept the price target at $4.50, unchanged from before.

4. Ryan Koontz from Needham has downgraded the rating to Buy and set a current price target of $5.00, down from $6.00.

Taking into account the ratings of nine Wall Street analysts, the consensus rating for 8×8 is currently Hold. This includes two buy ratings, six hold ratings, and one sell rating.

EGHT Stock Analysis: Bearish Sentiment and Potential Declines Ahead – January 2024 Update

On January 18, 2024, EGHT stock opened at $3.41, which was $0.03 higher than its previous close. However, the stock price dropped by $0.03, representing a 1.04% decrease. EGHT’s position in the middle of its 52-week range suggests a lack of significant highs or lows in the past year. Additionally, trading below its 200-day simple moving average could indicate a bearish sentiment and potential further declines in the future. Investors should carefully analyze these trends and consider other factors before making any investment decisions regarding EGHT stock.

EGHT Stock Shows Promising Performances with Increased Revenue and Improved Net Income: An Analysis Based on CNN Money Data

On January 18, 2024, EGHT stock showed promising performances based on the data provided by CNN Money. The company’s total revenue for the past year amounted to $743.94 million, marking a 16.58% increase compared to the previous year.

EGHT also witnessed a positive trend in its net income. Over the past year, the company reported a net loss of -$73.14 million. However, this figure improved by 58.3% compared to the previous year.

The earnings per share (EPS) of EGHT also showed significant improvement. Over the past year, the company reported an EPS of -$0.63, which marked a 59.23% increase compared to the previous year.

These positive financial indicators suggest that EGHT has made significant strides in its performance. The increase in total revenue and net income demonstrates the company’s ability to generate more revenue and reduce losses. Additionally, the improvement in EPS indicates a positive growth trajectory for EGHT.

Investors and shareholders may view these positive financial indicators as a sign of the company’s potential for future growth and profitability. However, it is important to conduct further analysis and consider other factors before making any investment decisions.

It is worth noting that these figures are based on the provided data from CNN Money. Investors should always conduct thorough research and consult with financial advisors to make informed investment decisions.

Tags: EGHT
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Capitalistic

Decline in Short Interest Indicates Positive Market Sentiment for Southern

Biotechnology Market Capitalization

Improvement in Market Sentiment for Adagene as Short Interest Decreases

Technology Data analytics Stock Bull Market

Ceridian to Acquire eloomi Revolutionizing People Development

Recommended

Marvell Technology Stock

Marvell Technology Emerges as Key Player in AI Infrastructure Boom

1 month ago
Novo Nordisk Stock

Danish Pharma Giant Novo Nordisk Faces Diverging Analyst Views

1 month ago
Finance_Investment (5)

Anticipation Builds as FirstService Prepares to Release Quarterly Earnings Report

2 years ago
Viking Therapeutics Stock

Acquisition Speculation Fuels Viking Therapeutics Stock Surge

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

DuPont Faces Critical Test as Quarterly Results Loom

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

Trending

BioNTech Stock
Analysis

BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise

by Andreas Sommer
November 6, 2025
0

BioNTech presents investors with a complex financial picture marked by contradictory signals. The German biotech firm reported...

Illumina Stock

China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally

November 6, 2025
Iovance Stock

Iovance Faces Critical Test as Q3 Earnings Approach

November 6, 2025
DuPont de Nemours Stock

DuPont Faces Critical Test as Quarterly Results Loom

November 6, 2025
Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise
  • China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally
  • Iovance Faces Critical Test as Q3 Earnings Approach

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com